TARA
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- TARA-002 achieves a 68% complete response rate at six months in BCG-unresponsive non-muscle invasive bladder cancerFeb 24, 2026
- Protara Therapeutics dosed first patient in Phase 3 THRIVE-3 Trial of IV Choline ChlorideJan 7, 2026
- Protara Therapeutics announced updated interim data from Phase 2 ADVANCED-2 trial of TARA-002 in BCG-naïve NMIBC patientsDec 3, 2025
- Protara Therapeutics announced positive interim results showing robust responses in ongoing Phase 2 STARBORN-1 trial of TARA-002 in pediatric patients with lymphatic malformationsNov 19, 2025